General
Preferred name
Gusacitinib
Synonyms
ASN-002 ()
ASN002 ()
Gusacitinib (ASN-002) ()
EN-3351 ()
EN3351 ()
GUSACITINIB HYDROCHLORIDE ()
EN3351 hydrochloride ()
ASN-002 HYDROCHLORIDE ()
EN-3351 HYDROCHLORIDE ()
ASN002 hydrochloride ()
Gusacitinib ()
P&D ID
PD098126
CAS
1425381-60-7
Tags
available
drug candidate
Drug indication
type II hypersensitivity reaction disease
atopic eczema
Solid tumour/cancer
Eczema
Lymphoma
Drug Status
investigational
Max Phase
2.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Gusacitinib (ASN002) is an orally bioavailable dual spleen tyrosine kinase (SYK)/pan Janus kinase (JAK) inhibitor that is being developed by Asana BioSciences. It is being evaluated for clinical efficacy in inflammatory and oncology settings. Not to be confused with Ascend Biopharmaceuticals immuno-oncology lead ASN-002, which is an engineered virus that expresses IFN-γ.
Gusacitinib is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1 . (GtoPdb)
Gusacitinib is one of the chemical structures (example 189) claimed in Asana Biosciences' patent WO2013028818A1 . (GtoPdb)
DESCRIPTION
Gusacitinib (ASN-002) is an orally active dual SYK/JAK kinase inhibitor with IC50 values of 5, 46, 4, 11 and 8 nM for SYK, JAK1, JAK2, JAK3 and TYK2, respectively. Gusacitinib rapidly and significantly suppressed key inflammatory pathways implicated in atopic dermatitis pathogenesis. Gusacitinib can be used in the research of chronic hand eczema and cancers such as basal cell carcinoma[1][2].
PRICE
118
DESCRIPTION
ASN-002 (Gusacitinib) is a dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with an IC50 value of 5-46 nM. It has anti-cancer activity.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Gusacitinib (ASN-002) (ASN-002) is spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitor (IC50: 5-46 nM).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
10
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
DrugBank
DrugMAP
Guide to Pharmacology
MedChem Express Bioactive Compound Library
PKIDB
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
16
Molecular Weight
460.23
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
3
cLogP
2.55
TPSA
134.06
Fraction CSP3
0.46
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
JAK
SYK
JAK,Syk
Pathway
Epigenetics
JAK/STAT Signaling
Protein Tyrosine Kinase/RTK
Stem Cell/Wnt
Angiogenesis
Chromatin/Epigenetic
Stem Cells
Tyrosine Kinase/Adaptors
Solubility
Soluble in DMSO
Source data
